Description
What is Teriparatide (PTH 1-34)?
Teriparatide is a synthetic 34-amino-acid peptide. It corresponds to the N-terminal fragment of parathyroid hormone (PTH). It is a parathyroid hormone receptor 1 (PTH1R) agonist. It is supplied by RCD bio as a research-grade lyophilized peptide in vials. It is available for:
- In vitro PTH1R receptor binding investigation
- Preclinical bone remodeling pathway research
- Osteoblast biology laboratory studies
A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications. However, the research-grade teriparatide supplied here is a distinct laboratory preparation. It is a 10mg lyophilized peptide vial produced for preclinical and in vitro research use only. It is not a pharmaceutical product, not a clinical preparation, and is not supplied for any human application. It is not a dietary supplement.
Chemical Properties
| Property | Detail |
| Product Type | Peptide |
| Product Name | Teriparatide (PTH 1-34) |
| Format | 10mg Lyophilized Vial |
| Application | Scientific / Research Use Only |
| CAS | 52232-67-4 |
| Molar Mass | 4,117.72 g/mol |
| Chemical Formula | C₁₈₁H₂₉₁N₅₅O₅₁S₂ |
| PubChem CID | 16133850 |
| IUPAC Name | H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ |
| Synonyms | PTH 1-34, Parathyroid Hormone Fragment 1-34, hPTH(1-34) |
| Physical Form | White to off-white lyophilized powder |
| Solubility | Soluble in sterile water or acetic acid solution; limited solubility in organic solvents |
| Storage | −20°C, protected from light and moisture |
| Classification | Research Use Only (RUO) |
The acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol) is also available from some suppliers. The values above reflect the free peptide entry for CAS 52232-67-4.
How Does Teriparatide (PTH 1-34) Work?
PTH1R Receptor Binding and cAMP Signaling Research:
Teriparatide has been investigated in preclinical cell and tissue models as a PTH1R agonist. In isolated receptor preparations and cell culture systems, PTH1R binding by teriparatide has been observed to activate adenylate cyclase, increasing intracellular cAMP levels and activating downstream protein kinase A signaling cascades. This receptor-mediated second messenger pathway is the primary mechanism under investigation in PTH1R pharmacology research.
Osteoblast Activation and Bone Formation Pathway Research:
Research in this area has investigated how PTH1R signaling may shift the balance between bone-forming and bone-resorbing cellular activity in experimental model systems.
RANKL/OPG Pathway Modulation Research:
In animal model studies, teriparatide has been investigated for its potential to modulate RANKL (receptor activator of nuclear factor kappa-B ligand) and osteoprotegerin (OPG) signaling. The interaction between PTH1R activation and the RANKL/OPG axis in bone remodeling model systems remains an active area of preclinical investigation.
Bone Remodeling Marker Research:
In preclinical bone remodeling model systems, teriparatide administration has been observed to modulate serum markers of bone formation and resorption, including osteocalcin and CTX-1, in a dose and frequency-dependent manner. This has made it a reference compound in preclinical studies investigating bone remodeling dynamics.
What are the Potential Research Applications of Teriparatide (PTH 1-34)?
In controlled laboratory environments, teriparatide vials have been investigated for the following research applications. These are observed in preclinical and in vitro contexts only.
- PTH1R receptor binding kinetics and structure-activity relationship studies
- Osteoblast differentiation and apoptosis pathway investigation in primary cell culture
- RANKL/OPG signaling axis research in preclinical bone remodeling model systems
- Comparative PTH fragment pharmacology studies against full-length PTH(1-84) analogs
- Bone formation and resorption marker modulation studies (in rodent preclinical models)
- cAMP second messenger signaling research in PTH1R-transfected cell line systems
What are the Potential Side Effects of Teriparatide (PTH 1-34)?
Researchers in preclinical and in vitro settings have noted the following observations.
- Observed modulation of calcium homeostasis pathways
- Potential to alter RANKL/OPG signaling balance in bone remodeling preparations
- Noted osteoblast apoptosis pathway interference in isolated cell studies
- Possible cAMP pathway overstimulation in receptor-overexpressing in vitro systems
- Dose and frequency-dependent variation in bone remodeling marker responses
- Long-term effects on calcium signaling networks remain under investigation
Risk & Handling
Teriparatide is a synthetic polypeptide PTH1R agonist under investigation in preclinical bone remodeling research.
Risk tier: HIGH. Researchers must observe the following precautions at all times.
Handling Precautions: Teriparatide should be handled exclusively in a controlled laboratory environment by trained personnel. Avoid skin and eye contact during reconstitution and handling. Use appropriate PPE at all times.
Exposure Risks: Teriparatide is a PTH1R agonist research peptide that is thought to modulate calcium homeostasis, cAMP signaling, and bone remodeling pathways in preclinical models. No human safety data has been established for the research-grade formulation supplied here.
Storage: Store lyophilized teriparatide at −20°C in a dry, dark environment. Protect from light, heat, and moisture at all times.
FAQs
What is the difference between research-grade and pharmaceutical teriparatide?
A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications under medical supervision. The research-grade vial preparation supplied by RCDbio is a distinct laboratory compound produced strictly for preclinical and in vitro research use.
Is Teriparatide (PTH 1-34) safe for human use?
No. The research-grade teriparatide supplied here is not approved by the FDA for human or veterinary use. RCDbio supplies it strictly for laboratory research purposes only.
How should Teriparatide (PTH 1-34) be stored?
Store vials at −20°C in a dry, dark environment, away from light, heat, and moisture. For storage-related queries, contact support@rcdbio.co.
What formulation variants of teriparatide exist for research purposes?
Teriparatide is commercially available in both free peptide form (CAS 52232-67-4, MW 4,117.72 g/mol) and acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol).
References
Jilka, R. L. (2007). Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone, 40(6), 1434–1446. https://pubmed.ncbi.nlm.nih.gov/17517365/
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation, 104(4), 439–446. https://pubmed.ncbi.nlm.nih.gov/10449436/
Disclaimer
Teriparatide (PTH 1-34) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.
The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.
ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co
Reviews
There are no reviews yet